» Articles » PMID: 29898682

Patient Care Activities by Community Pharmacists in a Capitation Funding Model Mental Health and Addictions Program

Overview
Journal BMC Psychiatry
Publisher Biomed Central
Specialty Psychiatry
Date 2018 Jun 15
PMID 29898682
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Community pharmacists are autonomous, regulated health care professionals located in urban and rural communities in Canada. The accessibility, knowledge, and skills of community pharmacists can be leveraged to increase mental illness and addictions care in communities.

Methods: The Bloom Program was designed, developed, and implemented based on the Behaviour Change Wheel and a program of research in community pharmacy mental healthcare capacity building. We evaluated the Bloom Program as a demonstration project using mixed methods. A retrospective chart audit was conducted to examine outcomes and these are reported in this paper.

Results: We collected 201 patient charts from 23 pharmacies in Nova Scotia with 182 patients having at least one or more follow-up visits. Anxiety (n = 126, 69%), depression (n = 112, 62%), and sleep disorders (n = 64, 35%) were the most frequent mental health problems. Comorbid physical health problems were documented in 57% (n = 104). The average number of prescribed medications was 5.5 (range 0 to 24). Sixty seven percent (n = 122) were taking multiple psychotropics and 71% (n = 130) reported taking more than one medication for physical health problems. Treatment optimization was the leading reason for enrollment with more than 80% seeking improvements in symptom management and daily functioning. There were a total of 1233 patient-care meetings documented, of which the duration was recorded in 1098. The median time for enrolling, assessing, and providing follow-up care by pharmacists was 142 min (mean 176, SD 128) per patient. The median follow-up encounter duration was 15 min. A total of 146 patient care encounters were 60 min or longer, representing 13.3% of all timed encounters.

Conclusions: Pharmacists work with patients with lived experience of mental illness and addictions to improve medication related outcomes including those related to treatment optimization, reducing polytherapy, and facilitating withdrawal from medications. Pharmacists can offer their services frequently and routinely without the need for an appointment while affording patient confidentiality and privacy. Important roles for pharmacists around the deprescribing of various medications (e.g., benzodiazepines) have previously been supported and should be optimized and more broadly implemented. Further research on the best mechanisms to incentivize pharmacists in mental illness and addiction's care should be explored.

Citing Articles

Between what is and what could be: a survey of pharmacists' practices, attitudes, and beliefs in the provision of mental health care.

Soubolsky A, Halpape K, Jorgenson D, Remillard A, Necyk C Int J Clin Pharm. 2023; 45(5):1192-1202.

PMID: 37682399 DOI: 10.1007/s11096-023-01633-6.


Pharmacist Administration of Long-Acting Injectable Antipsychotics to Community-Dwelling Patients: A Scoping Review.

Murphy A, Suh S, Gillis L, Morrison J, Gardner D Pharmacy (Basel). 2023; 11(2).

PMID: 36961024 PMC: 10037648. DOI: 10.3390/pharmacy11020045.


Mental health: "it is a subject where most pharmacists [or pharmacy] students have no more knowledge than the general public".

Gorton H, Strawbridge J, Macfarlane H J Pharm Policy Pract. 2023; 16(1):13.

PMID: 36694247 PMC: 9872065. DOI: 10.1186/s40545-022-00489-x.


Factors that influence pharmacists' efforts in addressing substance use in Nigeria: An exploratory study.

Rotimi K, Edeh F, Aiden J, Itiola A, Obamiro K Explor Res Clin Soc Pharm. 2022; 8:100189.

PMID: 36311825 PMC: 9615029. DOI: 10.1016/j.rcsop.2022.100189.


Bloom Program pharmacy teams' experiences providing mental health services during the COVID-19 pandemic.

Murphy A, Simon K, Pelletier E, Miller L, Gardner D Can Pharm J (Ott). 2022; 155(2):93-100.

PMID: 35300027 PMC: 8922227. DOI: 10.1177/17151635211065426.


References
1.
Hatah E, Braund R, Tordoff J, Duffull S . A systematic review and meta-analysis of pharmacist-led fee-for-services medication review. Br J Clin Pharmacol. 2013; 77(1):102-15. PMC: 3895351. DOI: 10.1111/bcp.12140. View

2.
Scheerder G, De Coster I, Van Audenhove C . Pharmacists' role in depression care: a survey of attitudes, current practices, and barriers. Psychiatr Serv. 2008; 59(10):1155-60. DOI: 10.1176/ps.2008.59.10.1155. View

3.
Houle S, Grindrod K, Chatterley T, Tsuyuki R . Paying pharmacists for patient care: A systematic review of remunerated pharmacy clinical care services. Can Pharm J (Ott). 2014; 147(4):209-32. PMC: 4212445. DOI: 10.1177/1715163514536678. View

4.
Crump K, Boo G, Liew F, Olivier T, So C, Sung J . New Zealand community pharmacists' views of their roles in meeting medicine-related needs for people with mental illness. Res Social Adm Pharm. 2011; 7(2):122-33. DOI: 10.1016/j.sapharm.2010.03.006. View

5.
Tannenbaum C, Tsuyuki R . The expanding scope of pharmacists' practice: implications for physicians. CMAJ. 2013; 185(14):1228-32. PMC: 3787169. DOI: 10.1503/cmaj.121990. View